Scientists discover that new antigen vaccine produces intratumoral T cell responses in stage Ib glioblastoma trials
January 21, 2019 Source: Ministry of Science and Technology
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];On December 19, 2018, researchers such as Harvard Medical School in the United States published an article entitled "Neoantigen vaccine generating intratumoral T cell responses in phase Ib glioblastoma trial" on Nature, and found that the new antigen vaccine is in stage Ib glioblastoma. Intratumoral T cell responses were generated in the trial.
The new antigen is derived from a tumor-specific protein-encoding mutation that is unaffected by central tolerance and produces a strong immune response and acts as a true antigen that promotes tumor rejection. In this study, the researchers demonstrated a strategy for the use of multi-epitope, personalized new antigen vaccines for tumor therapy in glioblastomas that typically have relatively low mutation loads and immune "cold" tumor microenvironments. The feasibility of this strategy was previously tested in high-risk melanoma patients. In the I/Ib phase, researchers used a personalized new antigen-targeted vaccine to immunize patients with newly diagnosed glioblastoma after surgical resection and conventional radiotherapy. Did not receive dexamethasone, a highly potent corticosteroid commonly used to treat cerebral edema in patients with glioblastoma - treated patients with circulating multifunctional new antigen-specific CD4+ and CD8+ T cell responses, and memory Both the immune response and the number of tumor infiltrating T cells increased. Using single-cell T-cell receptor analysis, the researchers demonstrated that new antigen-specific T cells from peripheral blood can migrate to intracranial glioblastoma. Therefore, the new antigen-targeted vaccine has the potential to change the immune environment of glioblastoma.
Maxillofacial Plate,Maxillofacial Titanium Plate,Titanium Maxillofacial Plates,X Maxillofacial Plates
Medton Medical , https://www.medtonmedical.com